Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 5Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Head and Neck Neoplasms 2Neoplasms, Squamous Cell 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 30Radiotherapy 24pembrolizumab 21Cetuximab 21Docetaxel 13Fluorouracil 12Radiotherapy, Intensity-Modulated 10Paclitaxel 9Radiation 8Nivolumab 7Everolimus 7Carboplatin 7Oxaliplatin 6Gemcitabine 5Surgical Procedures, Operative 4Radiosurgery 4Magnetic Resonance Spectroscopy 4Gefitinib 4Erlotinib Hydrochloride 4Amifostine 4Pemetrexed 3Filgrastim 3Capecitabine 3Bleomycin 3Biopsy 3zalutumumab 2spartalizumab 2pegfilgrastim 2niraparib 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Head and Neck Neoplasms × zalutumumab × Clear all
NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Genmab

Phase 1/2 Terminated
8 enrolled 10 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Genmab

Phase 1/2 Terminated
30 enrolled 13 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡